Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen

AMGN Bullish Diagonal Trade Targets a Price of $350 by October 18th

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, yet Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

What You Need to Know Ahead of Amgen's Earnings Release

Amgen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Kiplinger

Ark Invest CEO Cathie Wood Boosts Stake in Firms Making Breakthroughs in Gene Editing, AI Drug Development, and Obesity Drugs

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

International Business Times UK

3 Biotech Stocks Poised for May Surges

The use of advanced technologies, growing demand for personalized medicines, and rising investments in R&D are boosting the biotech industry’s prospects. Given this backdrop, investors could consider buying quality biotech stocks: Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and ANI Pharmaceuticals (ANIP). Read on.

StockNews.com

Stocks Close Higher as the Outlook Improves for Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +1.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.99%. US stock indexes Friday settled moderately higher, with the S&P 500 and Nasdaq 100...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stock Market Today: Stocks Soar on Apple Buyback News, Jobs Data

The main indexes rallied hard to end the week thanks to Apple's $110 billion stock repurchase plan and a big April payrolls miss.

Kiplinger

Stocks Climb as US Jobs Report Ramps Up Fed Rate Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) this morning is +0.86%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.65%. US stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

Barchart

Stocks Jump on Apple Earnings and Dovish Apr Payroll Report

The S&P 500 Index ($SPX ) (SPY ) this morning is +1.00%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.59%. US stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

Barchart

Stocks Climb Before the Open After Fed Decision, Apple Earnings on Tap

June S&P 500 E-Mini futures (ESM24) are up +0.58%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.77% this morning after Federal Reserve Chair Jerome Powell appeared to rule out the possibility of further interest-rate hikes, while investors looked ahead to a new round of U.S. economic data and…

Barchart

3 Best Dividend ETFs to Buy for Passive Income

High-yield dividend ETFs, such as SCHD, offer investors the ability to create a passive income stream for life at a relatively low cost.

Barchart

The FTC should embrace proactive problem-solving

The legal precedent would strongly discourage companies from trying to solve perceived problems with proposed transactions.

Fortune

Competition cop Lina Khan’s antitrust overreach is hurting U.S. competitiveness–and destroying billions of dollars in value

Antitrust overreach is hurting America's global competitiveness, with the FTC calculating industry concentration on a purely domestic basis.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

Chicago Sun-Times

Amgen cuts Horizon Therapeutics jobs at Deerfield office after acquisition

350 people will be laid off, many of them at Horizon’s U.S. base in Deerfield.

StockNews.com

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

All in: Drugmakers say yes, they'll negotiate with Medicare on price, so reluctantly

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

StockNews.com

3 Healthcare Stocks to Buy Today

The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV).

Fortune

Alphabet's Wing CFO Shannon Nash shares her unique path to the C-suite

Nash, who is also an award-winning film producer, names Debbie Allen as one of her greatest mentors.

Salon

The history of weight loss drugs

"It is no wonder demand for weight-loss drugs continues to soar"

The Conversation

Ozempic is in the spotlight but it's just the latest in a long and strange history of weight-loss drugs

Losing weight conveniently, cheaply, safely. That’s been the holy grail of weight-loss ever since 19th century English undertaker and weight-loss celebrity William Banting’s 1863 Letter on Corpulence spruiked his “miraculous” method of slimming down.

Kiplinger

Stock Market Today: Dow Outperforms as Amgen, Boeing Gain Ground

The main benchmarks closed higher ahead of this week's key inflation update.

The Independent UK

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

1 … 3 4 5 6

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.